Subscribe to Blog via Email
To burn or not to burn?
I once wrote a post about Pancreatic NET “to cut or not to cut”. You can read that here. Surgery for small pancreatic NETs remains controversial with most guidelines and study guidelines recommending surveillance for small primary tumours less than 2cm. There are exceptions to that, e.g. preventative surgery if the tumour is threatening important vessels and for functional cases where the surgery is palliative in nature. Contrast that against some patient perspectives where they just want it cut out (and some will ‘surgeon-shop’ until they find someone who will).
Most pancreatic NET are lower grades (e.g. Grade 1 and 2) well differentiated, most are non-functional, many are localised. Functional tumours such as Insulinoma are mostly small and localised.
A lack of sensitive and specific markers that can predict the patients most likely to have tumours that will grow and/or metastasise is still a work in progress, it’s a tough call as the biological behavior of an individual PNET remains unpredictable.
The Hippocratic oath can often guide doctors (and guideline writers) as radical surgery can present considerable morbidity (and a small risk of mortality) which might harm the patient more than the tumour.
Pancreatic NETs are growing as a research topic and in 2022, I noticed an increase in studies suggesting ablation as a method of removing sporadic small pancreatic NETs which is less risky and reduces the chance of severe morbidity but has comparable efficiency. The technique is not new but is not normally used in pancreatic NET cases. As science progresses, so will ablation techniques. But is there enough data to make this a standard of care?
I followed this thread on Twitter following the publishing of a small study as mentioned above. I witnessed the differing views. The author is known for pragmatism and often plays ‘devil’s advocate’ to provoke discussion (I’m sure he won’t mind me taking that view!)
Ablation vs Surveillance
I followed a thread on Twitter (see below) following the publishing of a small study as mentioned above. I witnessed the differing views, although the author is known for pragmatism and often plays ‘devil’s advocate’ to provoke discussion (I’m sure he won’t mind me taking that view!). The first graphic below is the thread comprising a tweet in 3 parts and then some comments from those following the thread in the second graphic. As you can see there it’s just as controversial as the surgery vs surveillance issue. One thing that was generally agreed was the need for more studies to confirm this is a viable option.
The study was suggesting Endoscopic Ultrasound (EUS) guided ethanol ablation, but other studies stick to EUS-guided radiofrequency ablation (RFA). I will attach samples of both below.
The final comment mentions a study (ASPEN) that I have already published indicating there is clinical evidence that surveillance is the best option in most cases. You can read that by clicking here.
Comparison of EUS-guided ablation and surgical resection for non-functioning small pancreatic neuroendocrine tumors: a propensity score matching study
Hoonsub So, M.D., Sung Woo Ko, M.D., PhD., Seung Hwan Shin, M.D., Eun Ha Kim, R.N., Jimin Son, M.D., SuHyun Ha, M.D., Ki Byung Song, M.D. PhD., Hwa Jung Kim, M.D. PhD., Myung-Hwan Kim, M.D., PhD., Do Hyun Park, M.D., Ph.D. PII: DOI: Reference: S0016-5107(22)02141-1 https://doi.org/10.1016/j.gie.2022.11.004 YMGE 13469
EUS-RFA for Pancreatic Insulinoma
This study conclusion is interesting.
EUS-RFA is safer than surgery and highly effective for the treatment of PI. If confirmed in a randomized study, EUS-RFA treatment can become first line therapy for sporadic PI.
Read the article abstract by clicking here
EUS-RFA of the pancreas: where are we and future directions
Gollapudi LA, Tyberg A. EUS-RFA of the pancreas: where are we and future directions. Transl Gastroenterol Hepatol. 2022 Apr 25;7:18. doi: 10.21037/tgh-2020-11. PMID: 35548478; PMCID: PMC9081919.
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Subscribe to Blog via Email
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
What is Carcinoid Syndrome? Carcinoid syndrome (CS) is the most frequent hormonal complication accompanying neuroendocrine neoplasms (NENs) and is defined by chronic diarrhoea and/or flushing in the
I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177) vs the efficacy of Everolimus (Afinitor). The latter is
November is always busier as I help spread awareness for 10th Nov (remembering that every day is 10th Nov on my site!). I also managed
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine